Breaking Finance News

A statement released earlier today by Maxim Group about Beigene Ltd (ADR) (NASDAQ:BGNE) raises the target price to $41.00

Beigene Ltd (ADR) (NASDAQ:BGNE) had its target price raised to $41.00 by Maxim Group in a report released 09/21/2016. The upped price target suggests a potential upside of 0.31% from the company's most recent close.

Having a price of $31.31, Beigene Ltd (ADR) (NASDAQ:BGNE) traded -2.21% lower on the day. The last closing price is up 5.12% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. BGNE has recorded a 50-day average of $29.56 and a two hundred day average of $29.01. Trade Volume was up over the average, with 79,609 shares of BGNE changing hands over the typical 54,953

See Chart Below

Beigene Ltd (ADR) (NASDAQ:BGNE)

Beigene Ltd (ADR) has a 52 week low of $22.51 and a 52 week high of $35.60 The company’s market cap is currently $0.

Brief Synopsis About Beigene Ltd (ADR) (NASDAQ:BGNE)

BeiGene, Ltd. is a biopharmaceutical company. The Company is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. It is developing its product candidate, BGB-3111, a potent and selective small molecule Bruton's tyrosine kinase (BTK) inhibitor, as a monotherapy and in combination with other therapies for the treatment of a range of lymphomas. It is developing its product candidate, BGB-A317, a humanized monoclonal antibody against the immune checkpoint receptor programmed cell death protein 1 (PD-1), as a monotherapy and as a combination agent for various solid-organ and blood-borne cancers. It is developing BGB-290, a molecularly targeted, orally available, potent and selective inhibitor of poly ADP ribose polymerase 1 (PARP1) and PARP2, as a monotherapy and in combination with other therapies for the treatment of homologous recombination deficient cancers. It is also developing BGB-283 for the treatment of cancers.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *